ARDX
Ardelyx Inc
23.58%
$3.35 - $4.14
Feb 7th 2023 - Mar 21st 2023
Mar, 4, 2023
I know it is goi g to change many lives on this bo... See more
Dec, 7, 2022
This is game changer for Kidney diseases patients.
KMPH
KemPharm Inc
-26.64%
$5.63 - $4.13
Feb 2nd 2023 - Mar 10th 2023
Feb, 24, 2023
"This long term study reinforces the efficacy... See more
Feb, 18, 2023
I recall an earlier posting last year of the same ... See more
AXSM
Axsome Therapeutics Inc
-4.66%
$65.95 - $62.88
Feb 7th 2023 - Mar 21st 2023
Mar, 16, 2023
That indicates excitement and demand from both phy... See more
Feb, 6, 2023
This will be a winner, the patient will reap significant rewards.
Mar, 4, 2023
I know it is goi g to change many lives on this board and as well as much needed for patients..
Dec, 7, 2022
This is game changer for Kidney diseases patients.
Dec, 6, 2022
but it does provide better life for patients without worrying too much and pill burden ..
Nov, 15, 2022
• Patients and treating physicians need and must have this product as an alternative treatment in their array.
Nov, 14, 2022
$ARDX we are going to get a lot of money and the most important, the patients are going to get a new wonderful life.
Nov, 14, 2022
Based on the totality of the results summarized in Table 43, the benefit-risk assessment for tenapanor is positive in patients with HP receiving maintenance dialysis.”
Nov, 13, 2022
I wish I could tha each one personally for helping us make a strong case and get this lifesaving medication into the hands of those that need it most: the patients.
Nov, 7, 2022
The recent survey done in partnership with with the National Kidney Foundation which showed that 90% of patients want more treatment options was absolutely brilliant and the timing was perfection.
Nov, 6, 2022
As a company committed to putting patients first, and as a CKD patient myself, we are proud of this collaborative effort that truly captures the voice of patients with kidney disease on dialysis."
Feb, 24, 2023
"This long term study reinforces the efficacy and safety of AZSTARYS as an important treatment option for healthcare professionals to consider when choosing the optimal ADHD therapy for their patients."
Feb, 18, 2023
I recall an earlier posting last year of the same clinic who said patients were doing well and parents were liking the appetite benefits
Jan, 23, 2023
$KMPH On the Facebook adhd forums, a mom said her sons doctor has had a few patients on azstarys and has had no complaints.
Jan, 20, 2023
$KMPH 700 new patients last week I'll take that!
Jan, 20, 2023
but again given the seasonality of ADHD in early school season combined with the Holidays, imo pretty OK. Actually gained more net new patients then Qelbree. .
Jan, 3, 2023
However, what I like best is that it is working on actual patients.
Dec, 30, 2022
Shows a strong base of patients.
Dec, 25, 2022
Here's to a great 2023 with scripts continuing increasing by 500 plus patients per week, great IH results and submitting to the fda our arimiclomol application
Dec, 19, 2022
And they are sooo patient
Dec, 19, 2022
So I am very positive this is a good treatment for me.
Mar, 16, 2023
That indicates excitement and demand from both physicians and patients on the efficacy.
Feb, 6, 2023
This will be a winner, the patient will reap significant rewards.
Jan, 13, 2023
I have treatment resistant depression and this is the first drug that has had an immediate mood-elevating effect on day 1 within 30 minutes of taking it.
Dec, 7, 2022
$AXSM Axsome Therapeutics announces that treatment with AUVELITY resulted in rapid, substantial, and durable improvements in cognitive and physical functioning in the EVOLVE open-label trial in major depressive disorder.
Nov, 28, 2022
$AXSM as an RN who works with agitated dementia patients on a daily basis, this is HUGE!
Nov, 28, 2022
Caregiver distress and burden, patient quality of life, and depressive symptoms were all statistically significantly improved compared to baseline after patients were treated with open-label AXS-05.